Business Wire

LabVantage Solutions and The Netherlands Forensic Institute (NFI) Partner to Advance Digital Transformation in Forensic Science

4.12.2024 13:30:00 CET | Business Wire | Press release

Share

—New Collaboration Enhances NFI’s IT Infrastructure with Advanced LIMS to Streamline Workflows, Improve Data Integrity, and Optimize Forensic Operations—

LabVantage Solutions, Inc., the leading provider of laboratory informatics solutions and services, including purpose-built LIMS platforms enabling rapid deployment at reduced costs, and The Netherlands Forensic Institute (NFI) today jointly announced a partnership to digitalize forensic laboratory workflows as part of NFI’s IT renewal initiative. A key aspect of this collaboration is the implementation of LabVantage Solutions’ Laboratory Information Management System (LIMS), which is designed to streamline NFI’s forensic operations by replacing fragmented processes and incorporating advanced capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204274659/en/

null

(Graphic: Business Wire)

NFI’s IT renewal initiative aims to modernize its infrastructure by replacing outdated manual systems with streamlined, automated workflows. Currently, the workflows involve multiple manual registrations across different systems, which can lead to time-consuming tasks and potential inconsistencies. The integration of LabVantage LIMS will unify data entry and enhance traceability, ensuring that data is efficiently recorded and utilized. It will also improve overall clarity and operational efficiency across forensic investigations, saving valuable time for all involved.

Peter Blom, Chief Information Officer of NFI, expressed his enthusiasm for the project: “This partnership marks a significant milestone in our journey to innovate and improve our forensic services. By integrating a sophisticated LIMS, we are setting a new standard in forensic science.”

“We are proud to work alongside NFI in their mission to enhance forensic operations,” said Michel Gerlicher, President, LabVantage International. “This collaboration will bring about a new era of efficiency and reliability in their laboratory workflows.”

The project includes contributions from Protinus, which served as the IT broker, and Capgemini, which is developing the sovereign cloud infrastructure to host the LIMS. The new system will integrate seamlessly into NFI’s operations, ensuring compliance with stringent security standards while enabling forensic experts to work faster and more confidently. By leveraging a secure, sovereign cloud infrastructure, the partnership will meet the highest standards of data protection and regulatory compliance, including BIO (Baseline Information Security for Government) and BBN (Baseline Information Security for Enterprises) requirements.

Alan Marcus, Chief Growth Officer at LabVantage Solutions, emphasized the broader implications of this alliance: “We are excited to see the real-life impact our investments in industry-specific solutions bring to our clients. With Software-as-a-Service (SaaS) becoming the de facto delivery standard, we expect vertical solutions to prove increasingly impactful, allowing clients to benefit from the latest innovations without being held back by past adaptations required by industry-agnostic software. NFI’s validation that our forensics solutions are fit for purpose is encouraging, and we are humbled to contribute to the fact-finding mission of NFI’s world-leading forensic laboratories.”

LabVantage Solutions, in joint effort with Protinus and Capgemini, will ensure the new system is secure and fully compliant with all required standards. By implementing LabVantage LIMS, NFI will streamline processes, enhance data accuracy, and improve data management, reinforcing its commitment to innovation and reliability. This partnership strengthens NFI’s role as a leader in delivering reliable forensic services to organizations around the world, while further establishing LabVantage Solutions’ prominence in the enterprise laboratory software solutions industry.

To learn more about LabVantage Solutions’ end-to-end informatics solutions for the complete forensic life cycle, please visit labvantage.com or contact us here.

About LabVantage Solutions
A recognized leader in enterprise laboratory software solutions, LabVantage Solutions dedicates itself to improving customer outcomes by transforming data into knowledge. Its highly configurable, 100% browser-based platform consists of LIMS, ELN, LES, SDMS, and advanced analytics, supporting seamless deployment into any environment. Serving over 1,500 customers across life sciences, pharmaceuticals, biobanking, food & beverage, forensics, and more, LabVantage Solutions empowers innovation, helps improve product quality, and ensures compliance with industry regulations. Headquartered in Somerset, NJ, with offices worldwide, LabVantage Solutions has driven laboratory digital transformation for over 40 years. For more information, visit labvantage.com.

About The Netherlands Forensic Institute (NFI):
The Netherlands Forensic Institute is dedicated to providing high-quality forensic services to support justice, peace, and security. The NFI has achieved this position by constantly improving its products and services. Science and innovation at the NFI are strongly driven by experiences from forensic practice. Through this innovative approach and commitment to excellence, the NFI serves both national and international clients, offering a wide range of forensic products and services. For more information, visit https://www.forensischinstituut.nl/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204274659/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 08:00:00 CEST | Press release

€50 million financing package from funds and accounts managed by BlackRock will support IQM to scale operations, accelerate product development, and strengthen its market position. The facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing as IQM prepares for public listing. IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This

Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations30.3.2026 07:45:00 CEST | Press release

Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/ Addressing Critical Trade Finance Challenges The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges. In

Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release

~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye